The immune system plays a significant role in the fight against cancer. However, as tumors grow they suppress the immune system and harness certain immune cell types to promote their own growth and spread. Cancer immunotherapy is one of the newest and most promising fields in cancer research and involves stimulating the patient’s immune response against their cancer by turning off these suppressive pathways. Cancer immunotherapy offers the potential to dramatically improve cancer treatments for millions of people.

ME Therapeutics has taken a novel approach to cancer immunotherapy. Using our combined expertise in tumour immunology, T cell biology and myeloid cell development, we are developing biological and small molecule drugs to target novel pathways involved in cancer-induced immune suppression. Our therapies have the potential to work on their own and in combination with other cancer immunotherapies across several cancer types.